Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • FAQ
    • Annual Report
    • Louder Than TB
  • Why New TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Pipeline
    • Discovery
    • Developing New Regimens
    • Engaging Communities
  • Access
    • Our Commitment
    • Understanding the TB Market
    • Child-friendly medicines
    • Pretomanid and BPaL
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
    • 20 Years of Impact
  • Donate

Search form

Publications

Keeping The Promise

  • Click here to download the full report

Accessing Improved TB Medicines for Children

  • Click here to download the full report

2020 Annual Report

Other Publications

Global Investments in Tuberculosis Research and Development

  • Click here to download the full report

Falling Short: Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis

  • Click here to download the report

New TB Regimens: What Countries Want

  • Click here to download the report

New Pathways for Childhood TB Treatment

  • Click here to download the full report

Pathway to Patients

Pathway to Patients is the first comprehensive analysis of how today's TB drugs reach patients on a global scale.

  • > Study Overview
  • > Compendium of Findings
  • > Country-specific results

The Economics of TB Drug Development

  • > Executive Summary
  • > Full report

Scientific Blueprint for TB Drug Development

  • > Executive Summary
  • > Full Blueprint

Factsheets & Brochures

Accessing Improved TB Medicines for Children

  • English
  • Français (French)
  • Español (Spanish)
  • русский (Russian)

About TB Alliance (Brochure)

  • English
  • Français (French)
  • Español (Spanish)
  • русский (Russian)

New Tools Factsheet

  • English
  • Français (French)
  • Español (Spanish)
  • русский (Russian)

PDP Model Factsheet

  • English
  • Français (French)
  • Español (Spanish)
  • русский (Russian)

Drug-Resistant TB Factsheet

  • English
  • Français (French)
  • Español (Spanish)
  • русский (Russian)

About TB Alliance (Factsheet)

  • English
  • Français (French)
  • Español (Spanish)
  • русский (Russian)

Annual Reports & Statements

2020 Annual Report

Gaining Ground

2019 TB Alliance Financial Statement

2019 Annual Report

Breaking Through

2018 TB Alliance Financial Statement

2018 Annual Report

A New Frontier

2017 TB Alliance Financial Statement

2017 Annual Report

Turning the Tide

2016 TB Alliance Financial Statement

2016 Annual Report

Making An Impact

2015 TB Alliance Financial Statement

2015 Annual Report

Reaching Further

2014 TB Alliance Financial Statement

2014 Annual Report

What it takes

2013 TB Alliance Financial Statement

2013 Annual Report

Change starts here

2012 TB Alliance Financial Statement

2012 Annual Report

Realizing the Promise

2011 TB Alliance Financial Statement

2011 Annual Report

Crossing Thresholds

2010 TB Alliance Financial Statement

2010 Annual Report

More Than Ever

2009 TB Alliance Financial Statement

2009 Annual Report

Accelerating the Pace

2008 TB Alliance Financial Statement

2008 Annual Report

Combating TB: What it Takes

2007 Annual Report

Advancing the Pathway: Novel approaches to getting faster and better TB drugs to patients

2005/2006 Annual Report

2004/2005 Annual Report

2003/2004 Annual Report

2002/2003 Annual Report

2001/2002 Annual Report

Join our mailing list and receive the latest news from TB Alliance.
Interests

Our Mission

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

Navigate

  • About
  • Why New TB Drugs?
  • R&D
  • Access
  • News
  • Donate

News Headlines

A Persistent Shortfall in TB Research and Development Funding
Astellas and TB Alliance Enter into a New Collaborative Research Agreement to Identify Lead Compounds for the Treatment of Tuberculosis
STAND Clinical Trial Results Published

Contact Us

Press Inquiries

Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

Jobs

View job openings at the TB Alliance

Report a Concern

New York:

40 Wall Street, 24th floor, New York, NY 10005 • +1 212 227 7540

Pretoria:

Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 12 991 6328
© 2021 The TB Alliance. All Rights Reserved. Site by Darby Communications Report a Concern